Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00312052 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 720
- Enrollment target
NCT00312052: Completed Phase 2 study, sponsored by Eisai.
NCT00312052 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 720 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (441% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00312052, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 720 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the safety and tolerability of E5555 in subjects with coronary artery disease.
Interventions
- DRUG Placebo
- DRUG E5555
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
What the finished NCT00312052 record still lists
NCT00312052 is an interventional study that assigns participants to a tested intervention. The registered 720 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (441% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00312052 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00312052 about?
NCT00312052 is a clinical study titled "Safety and Tolerability of E5555 and Its Effects on Markers of Intravascular Inflammation in Subjects With Coronary Artery Disease". The primary purpose of this study is to assess the safety and tolerability of E5555 in subjects with coronary artery disease.
What is the current status of trial NCT00312052?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 720 participants. The study started on 2007-09. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00312052?
The interventions under investigation include: Placebo (DRUG), E5555 (DRUG).
Who is sponsoring clinical trial NCT00312052?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00312052's enrollment target sits among peer trials
720 45th of 2000 higher than 1,956 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04916327 · 720 participants · NA
Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1
- NCT05047224 · 720 participants · NA
Addressing Disparities in Autism Spectrum Disorder Diagnosis Using a Direct-to-home Telemedicine Tool
- NCT05309395 · 720 participants · Phase 3
Food Prescriptions to Promote Affordable Diets
- NCT05466214 · 720 participants · NA
Systematic Efficacy Replication Study of Conjoint Behavioral Consultation in Elementary Schools
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia